We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

MDRNA, Inc. Announces Patent Allowance Covering Intranasal Formulations for Y2-Receptor Agonists

News   Apr 13, 2010

 
MDRNA, Inc. Announces Patent Allowance Covering Intranasal Formulations for Y2-Receptor Agonists
 
 
 

RELATED ARTICLES

A New Way to Build Novel Synthetic Biomolecules

News

Army scientists have discovered how to build novel synthetic biomolecule complexes that they believe are a critical step towards biotemplated advanced materials.

READ MORE

Cellular Drivers of Painful Childhood Food Allergy Characterized

News

An eight-year hunt for the cells that drive an extreme childhood food allergy (eosinophilic esophagitis, EoE) has identified a potential new way to treat the disease while also raising questions about a dietary supplement often taken to reduce bowel inflammation.

READ MORE

Blocking Protein’s Activity Restores Cognition in Old Mice

News

Brain cells called microglia serve as the brain’s garbage crew, scarfing up bits of cellular debris. But their underperformance in aging brains contributes to neurodegeneration. Could a strategy to restore this homeostasis be on the horizon?

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE